

HUMAN LIVER TISSUE LYSATE

| Catalog Number: NBP2-47088 | Extraction 1, soluble pro | ction 1, soluble protein fraction Human liver <i>tumor</i> tissue lysate Human liver <i>normal</i> tissue lysate (matched) | | | | | | |
|-------------------------------|--|--|---|-----------------------------------|--|--|--|--|
| | Extraction 2, insoluble p | protein fraction Human liver <i>tumor</i> tissu Human liver <i>normal</i> tiss | | 100 μg 100 μg | | | | |
| Diagnosis: | Hepatocellular carcinoma, Grade 2 | | | | | | | |
| Sex / Age: | Male, age 49. | | | | | | | |
| Concentration: | 1 mg/ml, 100 μ g/vial. | | | | | | | |
| | The vial is provided with a 10% overfill. Maximum recovery can be obtained by centrifuging the vial briefly to collect any solution on the cap and tube sides. | | | | | | | |
| Storage: | Aliquot single use volumes to avoid repeated freeze/thaw cycles. From time of receipt, this product is stable for 3 months at -20° C, or 12 months at -70° C. | | | | | | | |
| Lysate Preparation: | Tissue specimens are homogenized in modified RIPA buffer to obtain the soluble proteins, and centrifuged to clarify. The pellet was further extracted with a second buffer to obtain the less solub protein fraction. The lysate solution may appear turbid at cold temperatures due to insolubility of buffer components. The solution should clear upon warming to room temperature. | | | | | | | |
| | Extraction 1: Modified RIPA Buffer: | PBS, pH 7.4 1 mM EDTA 0.25% Na deoxycholate 1 mM Na ₃ VO ₄ | 1 μg/ml Aprotinin 1 μg/ml Pepstatin-A 1 μg/ml Leupeptin | 1 mM NaF 0.1% SDS 1 mM PMSF | | | | |
| | Extraction 2: | PBS, pH 7.4, 5.0 M Urea, 2.0 M Thiourea, 50mM DTT, 0.1% SDS | | | | | | |
| Application: | These lysates have not been subjected to denaturing or reducing conditions. This allows the tissu cell lysate to be used in a variety of applications; to study protein-protein interaction, ligand bind ELISA, immunoprecipitation, 1D and 2D gel electrophoresis, and Western blotting for the detect of specific protein targets. For use in 1D and 2D gel electrophoresis, the addition of a denaturing loading buffer with reducing agents may be required. | | | | | | | |
| | Buffer requirements for performing protein-protein interaction and ligand binding studies can vary significantly from RIPA buffer and may require modifications. In most cases, tissue lysates in RIPA buffer can be used, directly in standard ELISA and immunoprecipitation assays. | | | | | | | |
| | This material has tested negative for HbsAg, HIV 1/2, and HCV. Use UNIVERSAL PRECAUTION when handling. Human tissue derivatives must be treated as a potentially infectious agent and disposed of appropriately. | | | | | | | |
| Source: | Integrated Laboratory Services-Biotech (ILSbio), Chestertown, MD 21620 <u>www.ilsbio.com</u> ILS-8081 | | | | | | | |

www.novusbio.com - P: 303.730.1950 - P: 888.506.6887 - F: 303.730.1966 - technical@novusbio.com

Novus kits are guaranteed for 6 months from date of receipt

PATHOLOGY REPORT

| Catalog No. | NBP2-4 | 7088 | | | | | | | | |
|--|-------------------------------------|--|--------------------------------------|---|-------------------|------------------------------|------------|-----|--|--|
| Tissue: | Liver | Liver | | | | | | | | |
| Location: | Liver, ri | Liver, right lobe. | | | | | | | | |
| Diagnosis: | Hepatoc | Hepatocellular carcinoma, moderately differentiated. | | | | | | | | |
| Stage: | Not reco | Not recorded. | | | | | | | | |
| Grade: | 2 | | | | | | | | | |
| Sex: | Male | | | | | | | | | |
| Age: | 49 years | 5 | | | | | | | | |
| Appearance: | Macroscopic | | _ | | teristics | | <u>+/-</u> | | | |
| | Organ: Size: | Liver 12 cm. | | Encapsula Invaded: | ated: | | - | | | |
| | Color: | Gray-whi | | | agic: | | + | | | |
| | Consistency: | • | | Cystic degeneration: | | | - | | | |
| | Cut surface: | ice: Homogenous | | as Calcification: | | | - | | | |
| H ² -4-1 ² 44 | Call Hadailandian | | . / | C4 | | | . / | | | |
| Histologic pattern: | Cell distribution. Diffuse: | | +/- | Structu Streaming | <u>re / Patte</u> | rn: | <u>+/-</u> | | | |
| | Mosaic: | | + | Storiform | | | - | | | |
| | Necrosis: | | - | Fibrosis: | • | | - | | | |
| | Lymphocytic infiltrat | ion: | - Pallisading: | | | - | | | | |
| | Vascular invasion: | | - | Cystic degeneration: | | | - | | | |
| | Clusterized: | | + | Bleeding: Myxoid change: Psammoma body: | | | - | | | |
| | Alveolar formation: Indian file: | | + | | | | | | | |
| | mutan me. | | - | r sammon | lia bouy. | | - | | | |
| Cellular differentiation: | | | | | | | | | | |
| 00 | Squamous: | +/- | Adenon | natous: | +/- | Sarcon | atous: | +/- | | |
| | Squamoid: | - | Glandula | | + | Round ce | :11: | - | | |
| | Spindle: | - | Cell strati | | + | Spindle c | | - | | |
| | Keratin: | - | Secretion: Intracellular vacuole: | | - | Leiomyoblast: | | - | | |
| | Desmosome: Pearl: | - | | lar vacuole | | Lipoblast: Rhadomyoblast: | | - | | |
| | i cuii. | | Glandula | Tormation | | Rhadoling | oblast. | | | |
| | | | | | _ | | | | | |
| Nuclear atypia: | <u>Nuclear Appear</u> | ance: | | 0 | I | Π | III | | | |
| | Anisonucleosis: | chomatism: | | | Х | v | | | | |
| | Nucleolar prominent: | | | | | X X | | | | |
| | Multinucleated giant | | | | Х | | | | | |
| | Mitotic activity: | | | | | Х | | | | |
| | Nuclear grade: | | | | | Х | | | | |
| | | | | | | | | | | |